TOP HEADLINES

Editor's Corner

Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.

Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too

Some of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.

PhRMA kicks off new ad campaign to doctor pharma's tarred image

Big pharma knows that lawmakers are hopping mad over drug price increases. So the industry is launching an ad campaign to try to get back in politicians' good graces and repair its tarred image as the debate over drug pricing rages on.

 

NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent

Amgen's Repatha is in a market brawl with Sanofi and Regeneron's Praluent as the competitors rush to sew up as many OKs around the world as possible for the new-gen cholesterol fighters following their FDA approval last year within weeks of one another. Now Amgen has pulled ahead in England after the country's drug pricing watchdog has both changed course to cover Repatha for some patients, while dealing its competitors a blow with a rejection for Praluent.

Takeda-Teva JV 'could be a trendsetter' as Japan pushes for generics: analyst

Japan's efforts to cut drug costs have prompted at least one big deal this past year, with Takeda Pharmaceutical saying that it would team up with Teva Pharmaceutical Industries to respond to the country's generics push. These kind of deals will become more common, some analysts say, as Japan shifts away from branded meds and spurs development of low-cost copycats.

MORE NEWS

From Our Sister Sites

FiercePharmaAsia

The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.

FiercePharmaAsia

Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.